For patients who have spent years managing unpredictable and debilitating autoimmune conditions like lupus, the findings ...

Spherix Global Insights' Q1 2026 update of RealTime Dynamix(TM): Multiple Myeloma findings point to a clear inflection in treatment strategy, as physicians grow increasingly confident in CAR-T therapy ...

BCMA CAR T approvals (ide-cel 2021; cilta-cel 2022) deliver near-98% response in trials but require specialized centers, creating logistical constraints on access. Across >9 million UC patients, ...

Researchers at UC San Francisco have now developed a way to reprogram these cancer-fighting cells directly inside the body. This new method could remove the need for external manufacturing, ...

Finding an effective treatment for osteosarcoma, the most common type of bone cancer in children and young adults, has ...

Consider the case of patient WB, a 79-year-old male with recurrent diffuse large B cell lymphoma. He was referred for chimeric antigen receptor T-cell therapy (CAR-T), a recent game-changer for ...

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells ...

CAR T-cell therapy modifies a patient's immune cells to target cancer, offering potential cures for blood cancers like lymphoma and myeloma. Up to 40% of lymphoma patients may achieve remission after ...

Grace Miller was a 24-year-old law school student when she was diagnosed with multiple sclerosis ...

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T ...

FACE binds to CD71 on the T‑cell surface in CAR T cell preparation, and post-infusion, the same FACE molecules attach to CD71 ...

CAR T-cell therapy has revolutionized treatment for many blood cancers. However, the benefits of its use in the early stages of care remain uncertain. Chimeric antigen receptor (CAR) T-cell therapy ...